Back to Search
Start Over
Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival
- Source :
- Scientific Reports, Vol 7, Iss 1, Pp 1-11 (2017), Scientific Reports, Scientific reports, 7 (1
- Publication Year :
- 2017
- Publisher :
- Nature Publishing Group, 2017.
-
Abstract
- Immunotherapeutic strategies for glioblastoma, the most frequent malignant primary brain tumor, aim to improve its disastrous consequences. On top of the standard treatment, one strategy uses T cell activation by autologous dendritic cells (DC) ex vivo loaded with tumor lysate to attack remaining cancer cells. Wondering whether 'targeting' in vivo DCs could replace these ex vivo ones, immunogenic autologous tumor lysate was used to treat glioma-inoculated mice in the absence of ex vivo loaded DCs. Potential immune mechanisms were studied in two orthotopic, immunocompetent murine glioma models. Pre-tumoral subcutaneous lysate treatment resulted in a survival benefit comparable to subcutaneous DC therapy. Focussing on the immune response, glioma T cell infiltration was observed in parallel with decreased amounts of regulatory T cells. Moreover, these results were accompanied by the presence of strong tumor-specific immunological memory, shown by complete survival of a second glioblastoma tumor, inoculated 100 days after the first one. Finally, in combination with temozolomide, survival of established glioma in mice could be increased. Our results show the potential of immunogenic autologous tumor lysate used to treat murine glioblastoma, which will be worthwhile to study in clinical trials as it has potential as a cost-efficient adjuvant treatment strategy for gliomas.<br />SCOPUS: ar.j<br />info:eu-repo/semantics/published
- Subjects :
- 0301 basic medicine
medicine.medical_treatment
T cell
T-Lymphocytes
lcsh:Medicine
Article
03 medical and health sciences
Mice
0302 clinical medicine
Immune system
Phénomènes atmosphériques
In vivo
Glioma
Cell Line, Tumor
medicine
Immune Tolerance
Temozolomide
Animals
Humans
lcsh:Science
Multidisciplinary
business.industry
Brain Neoplasms
lcsh:R
Brain
Immunotherapy
Dendritic Cells
medicine.disease
Combined Modality Therapy
Survival Analysis
Mice, Inbred C57BL
030104 developmental biology
medicine.anatomical_structure
030220 oncology & carcinogenesis
Immunology
Female
lcsh:Q
business
Glioblastoma
Adjuvant
Ex vivo
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 20452322
- Volume :
- 7
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- Scientific Reports
- Accession number :
- edsair.doi.dedup.....3ad6147eedd0b9b621037bb2b5b2e1aa